Published on : Dec 26, 2016
ALBANY, NY, Dec 26, 2016: Currently, over 90 unique molecules, mostly antibodies, targeting inhibitory and stimulatory immunomodulators are in the clinical development stage as monotherapy or in combination with other checkpoint modulators or targeted cancer therapeutics. Another 31 molecules are under investigational new drug (IND) research program. The report discusses the various cancer immunomodulators projects under the research and development phase for different companies.
The report also furnishes information on competitor projects such as their drug codes, class of compound, target mechanism of action, product category, and the stage of research and development. The first report outlines progress in the Programmed Cell Death (PD-1) and PD-L1 immune checkpoint inhibitors in 2016. The PD-1 receptor antagonists immunotherapeutic approaches for treatment of cancer haven’t seen much progress so far. A knowledge of checkpoint signaling pathway entailing PD-1 receptor and its ligands (PD-L1/2) has made clear the role of these approaches to battle suppression of the human immunology caused by tumor. As a result they are considered important milestones in immunotherapeutic drug development.
The very first report analyses PD-1 receptor antagonists such as specific anti-PD-1 antibodies bispecific anti-PD-1 antibodies, and non-antibody PD-1 receptor antagonists. It also throws light on (PD-L1) inhibitors, which include specific anti-PD-L1 antibodies, bispecific anti-PD-L1 antibodies, and non-antibody PD-L1 inhibitors. Further, corporate PD-1 & PD-L1 immune checkpoint inhibitors that are currently in the research and development phase have been discussed too.
Click to get more details with TOC in a PDF Format: https://www.researchmoz.us/enquiry.php?type=S&repid=895857
The second report gives a lowdown on inhibitors of negative immune checkpoints CTLA-4, LAG-3, TIM-3, and others. Over 10 antibodies inhibiting negative immune checkpoints are in the development process as monotherapy or in combination with other checkpoint modulators or targeted cancer therapeutics. The report furnishes information on CTLA-4 antagonists such as yervoy (ipilimumab) monotherapy, yervoy (ipilimumab) combination with other therapeutics, yervoy (ipilimumab) combination with opdivo (nivolumab), tremelimumab combination with durvalumab, tremelimumab monotherapy, tremelimumab combination with other therapeutics, novel bispecific CTLA-4 antagonists, and novel specific CTLA-4 antagonists.
The third report presents a competitor analysis for activators of immune checkpoints CD27 agonists, CD40 agonists, Glucocorticoid-Induced Tumor Necrosis Factor Receptor (GITR) Stimulators, 4-1BB, OX40 agonists, and Inducible Co-Stimulator Molecule (ICOS) agonists. It also throws light on corporate immune checkpoint activators that are currently in the research and development phase.
The fourth report discusses tumor microenvironment modulation via IDO and TDO inhibitors such as epacadostat studies, novel IDO inhibitors, indoximod studies, novel TDO inhibitors, and dual IDO and TDO inhibitors. It also gauges possibilities of tumor microenvironment modulation via TGF-B/R, CXCR4, CSF-1R, CD47-SIRPa, Adenosine, STING, and others.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org